Literature DB >> 20813410

Plaque radiotherapy for juxtapapillary choroidal melanoma: tumor control in 650 consecutive cases.

Mandeep S Sagoo1, Carol L Shields, Arman Mashayekhi, Jorge Freire, Jacqueline Emrich, Jay Reiff, Lydia Komarnicky, Jerry A Shields.   

Abstract

PURPOSE: To evaluate treatment of juxtapapillary choroidal melanoma with plaque radiotherapy and to investigate the role of supplemental transpupillary thermotherapy (TTT).
DESIGN: Retrospective, comparative case series. PARTICIPANTS: We included 650 consecutive eyes with juxtapapillary choroidal melanoma within 1 mm of the optic disc.
METHODS: Eyes with juxtapapillary choroidal melanoma receiving plaque radiotherapy over a 31-year period from October 1974 to November 2005 were included in the study. The TTT and no TTT groups were analyzed separately and compared. MAIN OUTCOME MEASURES: Local tumor control, metastasis, and tumor-related mortality.
RESULTS: The median basal tumor diameter was 10 mm (range, 1.5-21) and median thickness was 3.5 mm (range, 0.5-14.8). In 481 eyes (74%), the tumor was directly adjacent to the optic disc and in 169 eyes (26%) the posterior tumor margin was between 0.1 and 1.0 mm from the optic disc. The circumpapillary extent of the tumor was <4 clock-hours in 321 eyes (50%), 4-8 clock-hours in 250 eyes (38%), and >8 clock-hours in 79 eyes (12%). Plaque radiotherapy using iodine-125 in 616 eyes (95%), cobalt-60 in 19 eyes (3%), iridium-192 in 12 eyes (2%), and ruthenium-106 in 3 eyes (<1%) delivered a median radiation dose of 8000 cGy (range, 3600-15 500) to the tumor apex and adjunctive TTT was used in 307 eyes (56%). Kaplan-Meier estimates for tumor recurrence, metastasis, and death were 14%, 11%, and 4% at 5 years and 21%, 24%, and 9% at 10 years, respectively. Eyes treated with additional TTT showed slight (statistically nonsignificant) reduction in recurrence and metastasis. Using multivariable analysis, factors predictive of tumor recurrence included foveolar tumor requiring TTT (hazard ratio, 5.07; P<0.001) and greater tumor thickness (hazard ratio, 1.29 per mm increase; P<0.001). Factors predictive of metastasis included greater tumor base (hazard ratio, 1.21 per mm increase; P<0.001) and increasing intraocular pressure (hazard ratio, 1.11 per mmHg increase; P = 0.020).
CONCLUSIONS: Plaque radiotherapy for juxtapapillary melanoma provides local tumor control in approximately 80% of eyes at 10 years. In subjects who received TTT, there was slight but nonsignificant improved local tumor control and lower metastatic rate.
Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20813410     DOI: 10.1016/j.ophtha.2010.06.007

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  10 in total

1.  Primary photodynamic therapy with verteporfin for small pigmented posterior pole choroidal melanoma.

Authors:  I D Fabian; A W Stacey; V Papastefanou; L Al Harby; A K Arora; M S Sagoo; V M L Cohen
Journal:  Eye (Lond)       Date:  2017-03-24       Impact factor: 3.775

Review 2.  Ocular phototherapy.

Authors:  A D Singh
Journal:  Eye (Lond)       Date:  2012-12-14       Impact factor: 3.775

3.  Juxtapapillary and circumpapillary choroidal melanoma: globe-sparing treatment outcomes with iodine-125 notched plaque brachytherapy.

Authors:  John V Hegde; Tara A McCannel; Colin A McCannel; James Lamb; Pin-Chieh Wang; Darlene Veruttipong; Robert Almanzor; D Jeffrey Demanes; Mitchell Kamrava
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-06-09       Impact factor: 3.117

4.  Cost-effectiveness of proton beam therapy for intraocular melanoma.

Authors:  James P Moriarty; Bijan J Borah; Robert L Foote; Jose S Pulido; Nilay D Shah
Journal:  PLoS One       Date:  2015-05-18       Impact factor: 3.240

Review 5.  Current and emerging treatment options for uveal melanoma.

Authors:  Patricia Rusa Pereira; Alexandre Nakao Odashiro; Li-Anne Lim; Cristina Miyamoto; Paula L Blanco; Macanori Odashiro; Shawn Maloney; Dominique F De Souza; Miguel N Burnier
Journal:  Clin Ophthalmol       Date:  2013-08-22

Review 6.  Treatment of uveal melanoma: where are we now?

Authors:  Jessica Yang; Daniel K Manson; Brian P Marr; Richard D Carvajal
Journal:  Ther Adv Med Oncol       Date:  2018-02-21       Impact factor: 8.168

Review 7.  Targeting Epigenetic Modifications in Uveal Melanoma.

Authors:  Pooneh Chokhachi Baradaran; Zuzana Kozovska; Alena Furdova; Bozena Smolkova
Journal:  Int J Mol Sci       Date:  2020-07-27       Impact factor: 5.923

Review 8.  Local treatment failure after globe-conserving therapy for choroidal melanoma.

Authors:  Melinda Y Chang; Tara A McCannel
Journal:  Br J Ophthalmol       Date:  2013-05-03       Impact factor: 4.638

9.  Intravitreal bevacizumab combined with plaque brachytherapy reduces melanoma tumor volume and enhances resolution of exudative detachment.

Authors:  Samuel K Houston; Nisha V Shah; Christina Decatur; Marcela Lonngi; William Feuer; Arnold M Markoe; Timothy G Murray
Journal:  Clin Ophthalmol       Date:  2013-01-22

10.  Outcomes and control rates for I-125 plaque brachytherapy for uveal melanoma: a community-based institutional experience.

Authors:  Aaron Wagner; Andy Chen; Taylor Cook; David Faber; Kirk Winward; William Sause
Journal:  ISRN Ophthalmol       Date:  2014-03-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.